Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

ClinicalTrials.gov ID: NCT00962637

Public ClinicalTrials.gov record NCT00962637. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Open-Label, Active-Controlled Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Approximately 4 to 5 million men in the U.S. are testosterone-deficient. Enclomiphene (trans-clomiphene) citrate (Androxal) was evaluated to determine if Androxal increased serum testosterone levels in men with secondary hypogonadism. Subjects were randomly assigned to 1 of 4 treatments groups. Appropriate amounts of medications were dispensed at each visit. Subjects took their medications orally or by rubbing it onto the skin (depending on the treatment assignment) once daily for up to 6 months. Treatment visits occurred at approximately 4-week intervals for Months 1, 2, and 3 and then at 6-week intervals for Months 4, 5, and 6.

Study identification

NCT ID
NCT00962637
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Repros Therapeutics Inc.
Industry
Enrollment
194 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 68 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2006
Primary completion
Apr 30, 2007
Completion
Apr 30, 2007
Last update posted
Feb 10, 2010

2006 – 2007

United States locations

U.S. sites
18
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
Alabama Clinical Therapeutics, LLC Birmingham Alabama 35235
Medical Affiliated Research Center, Inc. Huntsville Alabama 35801
Northern California Research Corp. Carmichael California 95608
Prime-Care Clinical Research Mission Viejo California 92691
Harbor-UCLA Medical Center Torrance California 90502
Chase Medical Research, LLC Waterbury Connecticut 06708
Southeastern Research Group, Inc. Tallahassee Florida 32308
Northeast Indiana Research, LLC Fort Wayne Indiana 46825
Commonwealth Biomedical Research Madisonville Kentucky 42431
The Center for Sexual Medicine at Sheppard Pratt Baltimore Maryland 21285
Office of Keith Pierce, MD Livonia Michigan 48152
Office of Michael Mall, MD Las Vegas Nevada 89109
Office of Stephen Miller, MD Las Vegas Nevada 89144
Advanced Biomedical Research, Inc. Hackensack New Jersey 07601
Office of Gary S. Karlin Lawrenceville New Jersey 08648
Medial Research Associates of Nashville Nashville Tennessee 37203
Urology San Antonio Research, PA San Antonio Texas 78229
Salt Lake Research Salt Lake City Utah 84107

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00962637, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 10, 2010 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00962637 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →